{"id":"https://openalex.org/W2893614917","doi":"https://doi.org/10.1097/01.cot.0000547228.96409.49","title":"New Treatments for Relapsed Hematologic Malignancies After alloHCT","display_name":"New Treatments for Relapsed Hematologic Malignancies After alloHCT","publication_year":2018,"publication_date":"2018-09-26","ids":{"openalex":"https://openalex.org/W2893614917","doi":"https://doi.org/10.1097/01.cot.0000547228.96409.49","mag":"2893614917"},"language":"en","primary_location":{"id":"doi:10.1097/01.cot.0000547228.96409.49","doi":"https://doi.org/10.1097/01.cot.0000547228.96409.49","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.cot.0000547228.96409.49","pdf_url":null,"source":{"id":"https://openalex.org/S4210170078","display_name":"Oncology Times","issn_l":"0276-2234","issn":["0276-2234","1548-4688"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology Times","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102705548","display_name":"Jacqueline Suen Garcia","orcid":"https://orcid.org/0000-0003-2118-6302","observed_orcids":["https://orcid.org/0000-0003-2118-6302","https://orcid.org/0000-0002-2599-7308"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jacqueline S. Garcia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.185,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.55288378,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"40","issue":"19","first_page":"1,2,26","last_page":"27"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11189","display_name":"Transplantation: Methods and Outcomes","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-hematologic-malignancies","display_name":"relapsed hematologic malignancies","score":0.9330000281333923},{"id":"https://openalex.org/keywords/allogeneic-hematopoietic-stem-cell-transplantation","display_name":"allogeneic hematopoietic stem cell transplantation","score":0.9330000281333923},{"id":"https://openalex.org/keywords/graft-versus-tumor-effect","display_name":"graft-versus-tumor effect","score":0.9670000076293945},{"id":"https://openalex.org/keywords/graft-versus-host-disease","display_name":"graft-versus-host disease","score":0.8939999938011169},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.8799999952316284},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9380000233650208},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8820000290870667},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.902999997138977},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.7559999823570251},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6110000014305115},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.7020000219345093},{"id":"https://openalex.org/keywords/post-transplant-recurrence","display_name":"post-transplant relapse","score":0.5519999861717224},{"id":"https://openalex.org/keywords/donor-t-cells","display_name":"donor T cells","score":0.6940000057220459},{"id":"https://openalex.org/keywords/small-molecule-inhibitors","display_name":"small molecule inhibitors","score":0.5320000052452087}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8424932360649109},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5894691944122314},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.5023922920227051},{"id":"https://openalex.org/C2780252810","wikidata":"https://www.wikidata.org/wiki/Q1455316","display_name":"Immunosuppression","level":2,"score":0.49371299147605896},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.4721772074699402},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4700901508331299},{"id":"https://openalex.org/C2779695342","wikidata":"https://www.wikidata.org/wiki/Q5296800","display_name":"Donor lymphocyte infusion","level":4,"score":0.4648958742618561},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.44927841424942017},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.433242529630661},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3976786732673645},{"id":"https://openalex.org/C2777408962","wikidata":"https://www.wikidata.org/wiki/Q1128050","display_name":"Hematopoietic stem cell transplantation","level":3,"score":0.3887428939342499}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1097/01.cot.0000547228.96409.49","doi":"https://doi.org/10.1097/01.cot.0000547228.96409.49","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.cot.0000547228.96409.49","pdf_url":null,"source":{"id":"https://openalex.org/S4210170078","display_name":"Oncology Times","issn_l":"0276-2234","issn":["0276-2234","1548-4688"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology Times","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2555972494","https://openalex.org/W2067948267","https://openalex.org/W2979789615","https://openalex.org/W3135091667","https://openalex.org/W2969262028","https://openalex.org/W2980895587","https://openalex.org/W1983186023","https://openalex.org/W2977738892","https://openalex.org/W4200527328","https://openalex.org/W2502489937"],"abstract_inverted_index":{"hematologic":[0,2,14,241,693,1209,1309,1573],"malignancies:":[1],"malignanciesRelapse":[3],"remains":[4,1200],"the":[5,160,182,208,215,221,228,315,389,434,457,504,512,603,640,650,660,715,720,746,840,846,861,910,950,978,1001,1014,1050,1058,1065,1090,1097,1106,1129,1157,1167,1184,1192,1201,1245,1256,1294,1337,1360,1364,1407,1416,1424,1434,1458,1486,1524,1528,1534,1569],"leading":[6],"cause":[7],"of":[8,47,92,106,159,211,319,323,356,372,391,460,467,508,552,560,566,579,585,594,605,618,649,654,662,686,692,722,735,748,756,769,842,851,863,915,952,961,984,1000,1016,1108,1123,1162,1186,1204,1259,1266,1296,1306,1316,1353,1363,1423,1433,1513,1530,1571,1585],"treatment":[9,951,1570],"failure":[10],"for":[11,131,237,288,297,529,753,927,949,969,1170,1247,1366,1448,1489,1498,1510,1544],"patients":[12,25,56,107,238,262,325,335,344,358,374,530,581,737,772,793,870,928,970,1003,1111,1248,1307],"with":[13,26,41,63,172,239,263,276,290,304,331,336,345,397,531,582,616,624,701,709,759,788,794,871,901,905,929,931,971,981,1112,1136,1148,1176,1250,1308,1312,1527],"malignancies":[15,265,694,1210,1310,1574],"who":[16,31,534,875,1139],"undergo":[17],"allogeneic":[18,739,1059],"hematopoietic":[19],"cell":[20,406,955],"transplantation":[21],"(alloHCT).":[22],"For":[23,728],"example,":[24,729],"acute":[27,567,1150],"myeloid":[28,601],"leukemia":[29,843,1042,1116,1152],"(AML)":[30],"relapse":[32,154,535,903,1109,1212],"shortly":[33],"after":[34,155,243,645,1213,1575],"transplant":[35,743],"have":[36,83,148,193,257,609,923,1226],"a":[37,42,74,104,145,232,300,386,452,544,573,679,689,696,706,730,1082,1164,1177,1187,1285,1303,1333,1399,1511],"particularly":[38],"poor":[39],"outcome,":[40],"3-year":[43],"overall":[44,925,994,1202],"survival":[45,926,995],"rate":[46],"<5":[48],"percent":[49,1422],"(Biol":[50,1008],"Blood":[51,1009,1119],"Marrow":[52,627,1010],"Transplant":[53,628,1011],"2015;454-459).":[54],"Such":[55],"commonly":[57],"receive":[58],"intensive":[59],"chemotherapy,":[60],"but":[61,255],"outcomes":[62,1246],"this":[64,123,655,670,1171,1230,1313,1402,1452,1507,1552],"approach":[65,124,224,656],"are":[66,100,475,488,672,725,876,1100,1236],"often":[67,446],"poor.":[68],"Therefore,":[69],"therapeutic":[70,195,465],"strategies":[71,713,837],"to":[72,143,152,299,363,429,675,718,818,823,834,845,867,891,986,1056,1067,1069,1128,1207,1239,1243,1280,1292,1427,1456,1466,1493],"augment":[73],"graft-versus-tumor":[75],"(GVT)":[76],"effect":[77,147],"without":[78,894],"eliciting":[79],"graft-versus-host":[80],"disease":[81,306],"(GVHD)":[82],"been":[84,150,610,1180],"explored.":[85],"However,":[86,503],"these":[87,132,212,561,1251,1282],"strategies,":[88],"such":[89,223,667,920,1223,1261,1297],"as":[90,921,1086,1224],"withdrawal":[91],"immunosuppression,":[93],"donor":[94,183],"lymphocyte":[95],"infusion,":[96],"and":[97,117,166,191,338,340,348,360,376,401,410,418,441,478,487,506,591,652,705,740,776,791,873,908,946,956,966,989,1102,1146,1159,1196,1220,1268,1270,1332,1359,1410,1443,1455,1472,1582,1589],"second":[98],"alloHCT":[99,1124,1576],"only":[101,998,1523],"successful":[102],"in":[103,197,214,227,260,302,354,370,377,388,415,433,481,491,511,550,572,613,635,639,659,669,714,785,799,869,909,977,1040,1049,1081,1089,1096,1110,1141,1153,1166,1229,1284,1326,1336,1468,1533,1551,1568],"minority":[105],"(Haematologica":[108],"2015;1222-1227).":[109],"Recent":[110],"advances":[111],"involving":[112],"pharmacologic":[113,1564],"agents":[114,213,1566],"including":[115,678,1134],"immunotherapies":[116],"small":[118],"molecule":[119],"inhibitors":[120,469,474,918,1095,1588],"suggest":[121,809],"that":[122,137,206,455,492,810,1211],"may":[125,178,526,539,813,831,887,1053,1289,1405],"be":[126,527,541,815,1054,1290,1557],"an":[127,202,398,633,1324],"important":[128,518],"new":[129,1563],"option":[130],"patients.":[133],"Pharmacologic":[134],"Immunotherapy":[135],"Therapies":[136],"stimulate":[138],"engrafted":[139],"donor-derived":[140,169],"T":[141,170,395,405],"cells":[142,171,177,396,844,1043],"elicit":[144],"GVT":[146,893,1195],"recently":[149],"explored":[151],"treat":[153],"alloHCT.":[156,1214],"The":[157,630,913,1121,1431,1439],"interaction":[158],"inhibitory":[161],"immune":[162,184,847,1218,1586],"checkpoint":[163,723,819,1587],"receptors":[164],"CTLA-4":[165,190,218],"PD-1":[167,192,431,461,468,473,509,524,606],"on":[168,175,1411],"cognate":[173],"ligands":[174],"tumor":[176,852],"help":[179],"tumors":[180,833],"evade":[181],"system.":[185],"Monoclonal":[186,1215],"antibodies":[187,1216],"directed":[188],"against":[189],"substantial":[194],"activity":[196,259,721,992,1018,1027,1048,1537],"solid":[198],"tumors,":[199],"which":[200,450,1063,1299],"provided":[201],"initial":[203],"clinical":[204,329,664,733,857,991,1334],"experience":[205,988],"informed":[207],"trial":[209,734,858,1085],"design":[210],"post-alloHCT":[216,229,435,608,771,801,878,911,1051,1091,1098,1168,1317],"setting.":[217,230,912],"blockade":[219,432,510,525,607,724],"was":[220,274,352,361,380,413,548,797,996],"first":[222,1154],"evaluated":[225],"specifically":[226],"In":[231,437,543,600,821],"pilot":[233,699,707],"phase":[234,270,680,697,731],"I":[235,681],"study":[236,273,682,700,708],"relapsed":[240,482,1004,1572],"malignances":[242],"alloHCT,":[244],"low":[245],"dose-ipilimumab":[246],"(0.1-3.0":[247],"mg/kg)":[248],"did":[249,256],"not":[250],"incite":[251],"clinically":[252],"significant":[253],"GVHD":[254,351,538,547,568,583,796,985,1199],"modest":[258],"three":[261,614,777],"lymphoid":[264],"(Blood":[266,470,569,598,1117],"2009;1581-1588).":[267],"A":[268,424,855,1072],"subsequent":[269,835],"I/Ib":[271],"multicenter":[272],"conducted":[275],"ipilimumab":[277,760,868],"dosed":[278],"at":[279,761,1005,1104,1328,1341,1355,1370,1419],"3":[280,286,295,762],"mg/kg":[281,284,763],"or":[282,307,483,879,1143],"10":[283,320,750,770],"every":[285,294,765],"weeks":[287,644],"induction,":[289],"maintenance":[291,967,1087,1174],"therapy":[292,1088,1175],"offered":[293],"months":[296],"up":[298],"year":[301],"those":[303,1135,1147],"stable":[305],"better":[308,1240,1558],"(N":[309,494,935],"Engl":[310,495,936],"J":[311,496,499,937],"Med":[312,497,938,1045],"2016;143-153).":[313],"At":[314],"highest":[316,1130],"dose":[317],"cohort":[318],"mg/kg,":[321],"seven":[322,741],"22":[324,1002],"(32%)":[326],"had":[327,563,632,778],"objective":[328],"responses":[330],"five":[332],"CRs":[333,775],"among":[334,343,422],"MDS":[337,872],"AML":[339,874,898,930,974],"two":[341,792],"PRs":[342],"multiple":[346],"myeloma":[347],"Hodgkin":[349,439,485,532],"lymphoma.":[350],"observed":[353,369,549,784,798,1160],"four":[355],"28":[357,373,757,766],"(14%)":[359],"responsive":[362],"corticosteroids.":[364],"Immune-related":[365,780],"adverse":[366,781,1581],"events":[367,782],"were":[368,577,588,783],"six":[371,551,559],"(21%),":[375],"one":[378,619,786,800,999],"instance":[379],"fatal.":[381],"Exploratory":[382],"correlative":[383],"studies":[384,520,668,1277],"showed":[385],"reduction":[387],"number":[390,1305],"circulating":[392],"CD4+":[393],"regulatory":[394],"increased":[399],"conventional":[400],"CD62L\u2212":[402],"effector":[403],"memory":[404],"populations.":[407],"Increased":[408],"CD8A":[409],"perforin":[411],"expression":[412,417],"seen":[414],"gene":[416,458],"corresponding":[419],"IHC":[420],"analysis":[421],"responders.":[423],"strong":[425],"rationale":[426],"also":[427,540,726,814,1023],"exists":[428],"explore":[430],"population.":[436],"particular,":[438],"lymphoma":[440,445,533],"primary":[442],"mediastinal":[443],"B-cell":[444],"feature":[447],"9p24.1":[448],"amplification,":[449],"is":[451,657,859,899,941,947,964,975,1078,1125,1323,1350,1437,1464,1483],"disease-specific":[453],"alteration":[454],"increases":[456],"dosage":[459],"ligands,":[462],"making":[463],"them":[464],"targets":[466,963],"2010;":[471],"3268-3277).":[472],"highly":[476],"active":[477,528,1103],"generally":[479],"well-tolerated":[480],"refractory":[484,590],"lymphoma,":[486],"now":[489,1126,1278],"FDA-approved":[490],"setting":[493,514,717,1052,1092,1099,1169],"2015;311-319;":[498],"Clin":[500],"Oncol":[501],"2016;3733-3739).":[502],"safety":[505,651,862],"efficacy":[507,653,1228],"post-transplant":[513,979],"remain":[515],"unknown.":[516],"Two":[517],"retrospective":[519],"suggested":[521],"that,":[522],"although":[523],"post-alloHCT,":[536],"frequent":[537],"observed.":[542],"French":[545],"study,":[546,575],"20":[553],"cases":[554,562],"(30%)":[555],"though":[556,1233],"notably":[557],"all":[558,1469],"prior":[564,866],"history":[565],"2017;2471-2478),":[570],"while":[571],"U.S.":[574],"there":[576],"17":[578,595,736],"31":[580,1540],"(55%)":[584],"whom":[586],"several":[587,1276],"steroid":[589],"fatal":[592],"(eight":[593],"cases,":[596],"47%)":[597],"2017;221-228).":[599],"malignancies,":[602],"results":[604],"reported":[611],"anecdotally":[612],"patients,":[615],"evidence":[617],"durable":[620,774,1070],"complete":[621,1415,1457],"remission":[622],"(though":[623],"GVHD)":[625],"(Bone":[626],"2017;317-320).":[629],"responder":[631],"increase":[634],"CD3+":[636],"T-cell":[637,827,1061],"infiltration":[638],"bone":[641],"marrow":[642],"4":[643],"nivolumab.":[646],"Further":[647],"assessment":[648],"needed":[658,1238],"context":[661],"prospective":[663,856],"trials.":[665],"Three":[666],"population":[671],"currently":[673],"underway":[674,1279],"address":[676],"this,":[677],"evaluating":[683,860],"lower":[684],"doses":[685],"nivolumab":[687,702],"across":[688],"broad":[690],"range":[691],"(NCT01822509),":[695],"II":[698,732],"(NIVALLO,":[703],"NCT03146468),":[704],"pembrolizumab":[710],"(NCT02981914).":[711],"Combination":[712],"post-transplantation":[716],"enhance":[719],"underway.":[727],"(10":[738],"autologous":[742],"patients)":[744],"tested":[745],"combination":[747,1273],"lenalidomide":[749],"mg":[751],"daily":[752],"21":[754],"out":[755],"days":[758],"administered":[764],"days.":[767],"Four":[768],"achieved":[773],"PRs.":[779],"patient":[787,802],"asymptomatic":[789],"hypothyroidism":[790],"dermatitis.":[795],"(Clin":[803],"Cancer":[804,1343,1372],"Res":[805],"2018;1011-1018).":[806],"Preclinical":[807],"data":[808,1235],"epigenetic":[811,829],"therapies":[812,830,886,1222],"promising":[816,990],"partners":[817],"inhibitors.":[820,1592],"addition":[822,914],"inducing":[824,895,1033],"cytotoxic":[825],"CD8+":[826,1060],"activation,":[828],"sensitize":[832],"immunotherapeutic":[836],"by":[838,849,1028,1036,1397,1485],"increasing":[839,1037],"\u201cvisibility\u201d":[841],"system":[848],"induction":[850],"antigen":[853],"expression.":[854],"decitabine":[864],"priming":[865],"either":[877],"transplant-na\u00efve":[880],"(NCT02890329).":[881],"Tyrosine":[882],"Kinase":[883],"Inhibitors":[884],"Targeted":[885],"offer":[888],"another":[889,942],"opportunity":[890],"promote":[892],"GVHD.":[896],"FLT3-mutated":[897],"associated":[900],"high":[902],"rates":[904,983],"standard":[906],"chemotherapy":[907],"tyrosine":[916,1590],"kinase":[917,1591],"(TKIs)":[919],"midostaurin":[922],"improved":[924],"activated":[932],"FLT3":[933,1075],"mutations":[934],"2017;454-464).":[939],"Sorafenib":[940],"oral":[943],"multikinase":[944],"inhibitor":[945],"approved":[948],"metastatic":[953],"renal":[954],"advanced":[957],"hepatocellular":[958],"carcinoma.":[959],"One":[960],"sorafenib's":[962],"FLT3-ITD,":[965],"sorafenib":[968,1017,1022],"FLT3-ITD":[972],"mutated":[973],"safe":[976,1101],"setting,":[980],"comparable":[982],"historical":[987],"(1-year":[993],"100%;":[997],"1":[1006,1514,1518],"year)":[1007],"2014;2042-2048).":[1012],"Although":[1013],"mechanism":[1015],"includes":[1019],"direct":[1020],"cytotoxicity,":[1021],"has":[1024,1064,1179],"indirect":[1025],"immune-mediated":[1026],"reducing":[1029,1105],"ATF4":[1030],"levels,":[1031],"thereby":[1032],"IL-15":[1034],"production":[1035],"IRF-7":[1038],"activation":[1039],"FLT3-ITD+":[1041],"(Nat":[1044],"2018;282-291).":[1046],"Sorafenib's":[1047],"due":[1055],"leveraging":[1057],"response,":[1062],"potential":[1066,1580],"lead":[1068],"remissions.":[1071],"more":[1073,1234,1449],"selective":[1074],"inhibitor,":[1076],"gilteritinib,":[1077],"under":[1079],"investigation":[1080],"large":[1083],"randomized":[1084,1188],"(NCT02997202).":[1093],"BCR-ABL":[1094],"risk":[1107,1131],"Philadelphia":[1113],"chromosome-positive":[1114],"(Ph+)":[1115],"2007;2791-2793;":[1118],"2017;1170-1172).":[1120],"use":[1122,1295],"limited":[1127],"Ph+":[1132,1149],"leukemias,":[1133],"chronic-phase":[1137],"CML":[1138],"present":[1140],"accelerated":[1142],"blast":[1144],"crisis,":[1145],"lymphoblastic":[1151],"remission.":[1155],"Given":[1156],"feasibility":[1158],"benefit":[1161,1302],"adding":[1163],"TKI":[1165,1178],"high-risk":[1172],"population,":[1173,1232],"widely":[1181],"adopted,":[1182],"despite":[1183],"lack":[1185],"study.":[1189],"Conclusions":[1190],"Tipping":[1191],"scales":[1193],"toward":[1194],"away":[1197],"from":[1198],"goal":[1203],"immune-based":[1205],"approaches":[1206],"treating":[1208],"targeting":[1217],"checkpoints":[1219],"targeted":[1221],"TKIs":[1225],"demonstrated":[1227],"challenging":[1231,1314],"still":[1237],"understand":[1241],"how":[1242],"improve":[1244],"treated":[1249],"approaches.":[1252],"Open":[1253],"questions":[1254,1425],"include":[1255],"optimal":[1257,1272],"timing":[1258],"deploying":[1260],"therapies,":[1262],"developing":[1263],"predictive":[1264],"biomarkers":[1265],"response":[1267],"toxicity,":[1269],"identifying":[1271],"partners.":[1274],"With":[1275],"answer":[1281],"questions,":[1283],"short":[1286],"time":[1287],"we":[1288],"able":[1291,1559],"optimize":[1293],"approaches,":[1298],"will":[1300],"ultimately":[1301],"greater":[1304],"faced":[1311],"situation":[1315],"relapse.":[1318],"JACQUELINE":[1319],"S.":[1320,1346,1374,1378,1381,1386],"GARCIA,":[1321],"MD,":[1322,1348,1383,1388],"Instructor":[1325],"Medicine":[1327,1354],"Harvard":[1329,1356],"Medical":[1330,1357,1479,1491,1502],"School":[1331,1358],"investigator":[1335],"Adult":[1338],"Leukemia":[1339,1369],"Program":[1340],"Dana-Farber":[1342,1371],"Institute.":[1344],"MATTHEW":[1345],"DAVIDS,":[1347],"MMSC,":[1349],"Assistant":[1351],"Professor":[1352],"Associate":[1361],"Director":[1362],"Center":[1365],"Chronic":[1367],"Lymphocytic":[1368],"Institute.Jacqueline":[1373],"Garcia,":[1375,1379],"MD:":[1376],"Jacqueline":[1377],"MDMatthew":[1380],"Davids,":[1382,1387],"MMSc:":[1384],"Matthew":[1385],"MMScRead":[1389],"This":[1390,1461,1536,1545],"Article":[1391],"&":[1392],"Earn":[1393,1395],"CME!":[1394],"CME":[1396,1429,1435,1459,1547,1553],"completing":[1398],"quiz":[1400],"about":[1401,1451],"article.":[1403],"You":[1404],"read":[1406],"article":[1408],"here":[1409],"our":[1412],"website,":[1413],"then":[1414],"quiz,":[1417],"answering":[1418],"least":[1420],"70":[1421],"correctly":[1426],"earn":[1428],"credit.":[1430],"cost":[1432],"exam":[1436],"$10.":[1438],"payment":[1440],"covers":[1441],"processing":[1442],"certificate":[1444],"fees.":[1445],"Visit":[1446],"http://CME.LWW.com":[1447],"information":[1450],"educational":[1453],"offering":[1454],"activity.":[1460,1535],"enduring":[1462,1508],"material":[1463,1509],"available":[1465],"physicians":[1467],"specialties,":[1470],"nurses,":[1471],"other":[1473],"allied":[1474],"health":[1475],"professionals.":[1476],"Lippincott":[1477,1500],"Continuing":[1478,1490,1501],"Education":[1480,1492,1503],"Institute,":[1481,1504],"Inc.,":[1482,1505],"accredited":[1484],"Accreditation":[1487],"Council":[1488],"provide":[1494],"continuing":[1495],"medical":[1496],"education":[1497],"physicians.":[1499],"designates":[1506],"maximum":[1512],"AMA":[1515],"PRA":[1516],"Category":[1517],"Credit\u2122.":[1519],"Physicians":[1520],"should":[1521,1556],"claim":[1522],"credit":[1525],"commensurate":[1526],"extent":[1529],"their":[1531],"participation":[1532],"expires":[1538],"October":[1539],"2019.":[1541],"Learning":[1542],"Objectives":[1543],"Month's":[1546],"Activity:":[1548],"After":[1549],"participating":[1550],"activity,":[1554],"readers":[1555],"to:":[1560],"1.":[1561],"Identify":[1562],"immunotherapy":[1565],"used":[1567],"transplantation.":[1577],"2.":[1578],"Examine":[1579],"serologic":[1583],"effects":[1584]},"counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2018-10-05T00:00:00"}